BNTX

BNTX

USD

BioNTech SE American Depositary Share

$104.780+0.460 (0.441%)

实时价格

Healthcare
生物技术
德国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$104.320

最高价

$107.000

最低价

$104.215

成交量

0.13M

公司基本面

市值

25.2B

所属行业

生物技术

国家/地区

Germany

交易统计

平均成交量

0.85M

交易所

NMS

货币

USD

52周价格范围

最低价 $81.2当前价 $104.780最高价 $129.27

相关新闻

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140

HC Wainwright & Co. analyst Robert Burns maintains BioNTech with a Buy and raises the price target from $136 to $140.

查看更多
HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140
GlobeNewswire

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging

查看更多
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
GlobeNewswire

BioNTech to Host Innovation Series R&D Day on November 11, 2025

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00

查看更多
BioNTech to Host Innovation Series R&D Day on November 11, 2025
GlobeNewswire

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the

查看更多
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
Analyst Upgrades

JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120

JP Morgan analyst Jessica Fye maintains BioNTech with a Neutral and lowers the price target from $121 to $120.

查看更多
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120
GlobeNewswire

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology